Paul A. Friedman has demonstrated a pronounced selling bias in his trading activity, particularly concentrated in shares of Madrigal Pharmaceuticals (MDGL). Over his 85 reported transactions, he has sold over $101.7 million worth of MDGL stock while purchasing just $2.7 million, a nearly 40-to-1 ratio favoring disposals. His recent activity reinforces this trend, with 24 sales executed on January 9, 2026, totaling approximately $7.8 million. These disposals ranged from smaller transactions like $4,424 and $42,600 to seven-figure sales, including a $1.27 million and $1.27 million block. The consistency of these sales—all executed on the same day across varying dollar amounts—suggests a structured divestment strategy rather than sporadic trading. Friedman’s trading history is exclusively tied to MDGL, indicating a singular focus on this biopharmaceutical holding. While the filings do not specify his role at the company, the scale and persistence of his selling activity over time point to a deliberate reduction in exposure to Madrigal stock. The absence of any recent buys further underscores a clear directional bias toward liquidation in early 2026.
AI-assisted summary